Medtronic says it agreed to settle about 950 product liability lawsuits filed over its controversial Infuse bone graft product for $22 million, but admits no wrongdoing. Medtronic (NYSE:MDT) said today that it agreed to pay $22 million to settle an estimated 950 lawsuits filed over its controversial Infuse bone graft product, admitting to no wrongdoing in what it termed a "compromise" of disputed claims. Medtronic said it stands behind Infuse, saying it's been used in more than 1 million patients, and pledged to "vigorously defend the product and company actions in the remaining cases."
Help employers find you! Check out all the jobs and post your resume.
